EOLS
Evolus, Inc.NASDAQHealthcare$4.03+3.23%ClosedMarket Cap: $262.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-11.61
P/S
0.91
EV/EBITDA
-13.45
DCF Value
$9.52
FCF Yield
-17.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.8%
Operating Margin
-12.5%
Net Margin
-17.4%
ROE
267.8%
ROA
-22.9%
ROIC
-24.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $90.3M | 60.8% | $-291.0K | $130.0K | $0.00 | — |
| FY 2025 | $297.2M | 64.9% | $-37.6M | $-51.6M | $-0.80 | — |
| Q3 2025 | $69.0M | 66.5% | $-11.5M | $-15.7M | $-0.24 | — |
| Q2 2025 | $69.4M | 65.3% | $-10.2M | $-17.1M | $-0.27 | — |
| Q1 2025 | $68.5M | 68.1% | $-15.2M | $-18.9M | $-0.30 | — |
| Q4 2024 | $78.9M | 63.8% | $-2.3M | $-6.8M | $-0.11 | — |
| FY 2024 | $266.3M | 68.5% | $-34.4M | $-50.4M | $-0.81 | — |
| Q3 2024 | $61.1M | 70.2% | $-15.5M | $-19.2M | $-0.30 | — |
| Q2 2024 | $66.9M | 70.3% | $-7.7M | $-11.3M | $-0.18 | — |
| Q1 2024 | $59.3M | 68.3% | $-8.9M | $-13.1M | $-0.22 | — |
| Q4 2023 | $61.0M | 63.6% | $-8.6M | $-11.8M | $-0.21 | — |
| FY 2023 | $202.1M | 69.5% | $-49.2M | $-61.7M | $-1.08 | — |